Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
IMDX Stock Chart & Stats
$6.04
--
Market closed
$6.04
--
Day’s Range― - ―
52-Week Range$1.92 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$175.44M
Enterprise Value$75.80M
Total Cash (Recent Filing)$18.69M
Total Debt (Recent Filing)$3.13M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Apr 01, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding28,619,750
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.53
Price to Sales (P/S)16.54
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue17.22
Enterprise Value/Gross Profit31.46
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$8.50Price Target Upside40.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIMDX has proceeded into Phase 3 which includes a ~125 patient validation trial and still expects to sign-on at least 20 transplant centers by the end of 2025.
FDA ApprovalIMDX reaffirmed its goal to submit its GraftAssureDx kidney test to the FDA by the end of 2025, and expects to obtain FDA approval around mid-2026.
PartnershipsIMDX remains confident in its partnership with BioRad, whereby BioRad and IMDX will comarket GraftAssure inside the US/Germany, and BioRad will take the commercial lead in the rest of the world.
Bears Say
Cash BurnIMDX continues to make progress in managing its cash burn though it may exceed its ~$6M per quarter target.
Earnings Per ShareEPS of -$0.34 missed Street's -$0.21.
Gross MarginsQ3 GMs came in at 53%, down from 67% in Q2.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $1.92 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $175.44M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Apr 01, 2026 which is in 127 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Nov 10, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.21 by $0.01.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 28,619,750 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.21. Following the earnings report the stock price went up 10.588%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (40.73% Upside)
$8.50 (40.73% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-32.39%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a generally positive outlook with significant advancements in product development and financial stability. However, the uncertainty due to the government shutdown and slower-than-expected clinical trial enrollment presents challenges.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$8.50
▲(40.73% Upside)